Search

Aim: To study the efficacy and safety of bulevirtide, the HBV and HDV entry inhibitor., Materials and Methods: Analysis of the results of using bulevirtide in randomized controlled open-label comparative studies MYR202 and MYR203 in 56 patients with chronic hepatitis D and compensated cirrhosis, in monotherapy and combination with pegylated interferon alpha-2a (PEG-IFN)., Results: Monotherapy with bulevirtide for 24 weeks in the MYR202 study in 46 patients with compensated liver cirrhosis demonstrated: 1) a high rate of virological (100%) and biochemical response (alanine aminotransferase normalization rate 45.7%), 2) superiority of bulevirtide in efficacy over the control group (tenofovir), 3) comparability of treatment efficacy in patients with and without cirrhosis, 4) no progression of liver fibrosis with elastometry in most patients. Treatment with bulevirtide in monotherapy and combination with PEG-IFN for 48 weeks in 10 patients with compensated liver cirrhosis in the MYR203 study was accompanied by a high rate of virological response (80%) and normalization of alanine aminotransferase (70%). Bulevirtide was well tolerated, there was no deterioration in tolerability compared with patients without cirrhosis, there were no serious adverse events and cases of treatment cancellation due to adverse events., Conclusion: Bulevirtide is recommended as the first line of treatment for chronic hepatitis D in patients with compensated cirrhosis in monotherapy and combination with PEG-IFN.

The preparation chophitol in complex treatment significantly improves the life quality of patients with chronic hepatitis and liver cirrhosis of viral etiology. It normalizes the index of cytolysis (ALT, AST) in patients with chronic hepatitis of viral etiology with moderate activity, and also the level of bilirubin in significantly short periods of time. In patients with liver cirrhosis of viral etiology classified as Child-Pugh A and B after the treatment with chophitol has been normalized index of overall protein and albumin, and in patients with liver cirrhosis classified as Child-Pugh class C appeared a tendency to the normalization of overall protein and albumin and prothrombin index, also creatinine in blood, which was accompanied with increased diuresis. The preparation is not expensive, is well tolerated. There has been observed no side effects on the treatment.